Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 458 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Abramson Cancer Center at Penn Medicine Clear all
Completed Phase 2 Interventional

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

NCT01019187
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Quality of Life Assessment, Questionnaire Administration, Placebo, Fatigue assessment and management, Sleep disorder therapy, Armodafinil, Management of Therapy, Cognitive Assessment, Management of therapy and complications, Fatifue assessment and management
Procedure · Other · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

NCT04798664
View directory record Official record
Conditions
Smoking Cessation
Interventions
Removal of Financial Barriers, Financial Incentives, Mobile Health Application
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Oakland, California • Detroit, Michigan • Danville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 4:38 PM EDT
Terminated Early Phase 1 Interventional

A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

NCT03427021
View directory record Official record
Conditions
GI Patients on Oxaliplatin Containing Regimen
Interventions
Oxaliplatin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Infusional C-myb ASODN in Advanced Hematologic Malignancies

NCT00780052
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
c-myb AS ODN
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2016 · Synced Jul 23, 2026, 4:38 PM EDT
Recruiting Phase 1 Interventional

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

NCT03760575
View directory record Official record
Conditions
Mesotheliomas Pleural
Interventions
Pembrolizumab, Indocyanine Green (ICG) Image-Guided Surgery, Cisplatin, Pemetrexed
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 23, 2026, 4:38 PM EDT
Completed No phase listed Observational

DIBH Proton Planning

NCT01386697
View directory record Official record
Conditions
Lung Cancer, Breast Cancer, Gastrointestinal, Lymphomatous Malignancies
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 23, 2026, 4:38 PM EDT
Recruiting Early Phase 1 Interventional

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

NCT07278986
View directory record Official record
Conditions
Endometrial Cancer, Near Infrared Fluorescence Imaging, CYTALUX (Pafolacianine) Injection, Planned Diagnostic Laparoscopies
Interventions
CYTALUX™ (pafolacianine), 1788 4K Camera System with Advanced Imaging Modality
Drug · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy

NCT02130427
View directory record Official record
Conditions
Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer, Rectal Cancers, Gynecological Malignancy Requiring Definitive Radiotherapy
Interventions
CT scan
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 4:38 PM EDT
Terminated Phase 2 Interventional Results available

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

NCT03781960
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Abemaciclib, Nivolumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 23, 2026, 4:38 PM EDT
Recruiting No phase listed Observational

Assessment of Geriatric Evaluations Impact on New AML Guidance

NCT05909501
View directory record Official record
Conditions
AML, Adult
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 23, 2026, 4:38 PM EDT
Active, not recruiting Not applicable Interventional

Comparing Two Ways to Manage Head and Neck Lymphedema

NCT05182229
View directory record Official record
Conditions
Head and Neck Cancer, Lymphedema
Interventions
Home-based (a hybrid model) CDT, Clinic-based CDT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Cherry Hill, New Jersey • Philadelphia, Pennsylvania • Willow Grove, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 4:38 PM EDT
Withdrawn No phase listed Observational

Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

NCT02993536
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Biospecimen Collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer

NCT02316002
View directory record Official record
Conditions
Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 23, 2026, 4:38 PM EDT
Completed No phase listed Observational

Cardiovascular Effects of CART Cell Therapy

NCT04026737
View directory record Official record
Conditions
Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular, Immunotherapy
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

Suitability of DCE-MRI for Detection of Vascular Changes After VBT

NCT01991808
View directory record Official record
Conditions
Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus
Interventions
Radiotherapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jul 23, 2026, 4:38 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

NCT03083288
View directory record Official record
Conditions
Breast Cancer
Interventions
[18F]FluorThanatrace
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 4:38 PM EDT
Completed No phase listed Observational

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

NCT02380196
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Early Phase 1 Interventional

Autophagy Induction After Bortezomib for Myeloma

NCT01594242
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)

NCT02906397
View directory record Official record
Conditions
ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
Interventions
Galunisertib 150mg by mouth twice a day, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer

NCT02159703
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
TORS, Adjuvant Radiation Therapy
Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Phase 1 Interventional

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

NCT01548807
View directory record Official record
Conditions
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

Clinical Utility of a Low-Cost Hand-Held Breast Scanner

NCT02762565
View directory record Official record
Conditions
Symptomatic Breast Lump
Interventions
PEFS system (Product Name: Intelligent Breast Exam™ or iBE™
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

NCT00472693
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Abraxane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 23, 2026, 4:38 PM EDT
Completed Not applicable Interventional

An Analysis of Medication Adherence Using Televideo and Telephonic Monitoring and Utilization of an Education Protocol

NCT06696521
View directory record Official record
Conditions
Adherence, Medication, Cancer
Interventions
Intervention A- Telephone, Intervention B- Televideo
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 23, 2026, 4:38 PM EDT